Pharmacokinetic and Pharmacodynamic Interaction of Nadolol With Itraconazole, Rifampicin and Grapefruit Juice in Healthy Volunteers

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of clinical pharmacology

• Publication date

  2013-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/jcph.95PMID 23677858
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Nadolol: A Review of its Pharmacological Properties and Therapeutic Efficacy in Hypertension and Angina Pectoris

  2012cited by this paper
• Microdosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1), and Interaction (Grapefruit Juice) Profiles of Celiprolol Following the Oral Microdose and Therapeutic Dose

  2012cited by this paper
• Transporter-mediated drug-drug interactions.

  2011cited by this paper
• Transporter‐Mediated Drug–Drug Interactions

  2011cited by this paper
• The effects of the SLCO2B1 c.1457C>T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans

  2011cited by this paper
• Fruit juice inhibition of uptake transport: a new type of food-drug interaction.

  2010cited by this paper
• Species Difference in the Effect of Grapefruit Juice on Intestinal Absorption of Talinolol between Human and Rat

  2010cited by this paper
• Itraconazole and Rifampin Alter Significantly the Disposition and Antihistamine Effect of Ebastine and Its Metabolites in Healthy Participants

  2010cited by this paper
• Evaluation of In Vivo P-Glycoprotein Phenotyping Probes

  2010cited by this paper
• Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol.

  2009cited by this paper
• Biopharmaceutics classification of selected beta-blockers: solubility and permeability class membership.

  2007cited by this paper
• Induction of Intestinal P‐glycoprotein by St John's Wort Reduces the Oral Bioavailability of Talinolol

  2007cited by this paper
• Naringin is a Major and Selective Clinical Inhibitor of Organic Anion‐Transporting Polypeptide 1A2 (OATP1A2) in Grapefruit Juice

  2007cited by this paper
• Intestinal Drug Transporter Expression and the Impact of Grapefruit Juice in Humans

  2007cited by this paper
• Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms.

  2006cited by this paper
• Effect of rifampicin on the pharmacokinetics of atenolol.

  2006cited by this paper
• Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein.

  2006influential reference
• Elucidating the Effect of Final-Day Dosing of Rifampin in Induction Studies on Hepatic Drug Disposition and Metabolism

  2006cited by this paper
• Grapefruit Juice Ingestion Significantly Reduces Talinolol Bioavailability

  2005cited by this paper
• Effect of itraconazole on the pharmacokinetics of atenolol.

  2005cited by this paper
• Transporters and drug therapy: Implications for drug disposition and disease

  2005cited by this paper
• Effects of orange juice on the pharmacokinetics of atenolol

  2005cited by this paper
• Orange juice substantially reduces the bioavailability of the β‐adrenergic–blocking agent celiprolol

  2004cited by this paper
• Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System

  2004cited by this paper
• Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects.

  2003cited by this paper
• Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol

  2003cited by this paper
• Rifampicin reduces plasma concentrations of celiprolol

  2003cited by this paper
• Fruit juices inhibit organic anion transporting polypeptide–mediated drug uptake to decrease the oral availability of fexofenadine

  2002cited by this paper
• The effect of rifampin administration on the disposition of fexofenadine

  2001cited by this paper
• The effect of rifampin treatment on intestinal expression of human MRP transporters.

  2000cited by this paper
• Induction of P‐glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: A new type of drug/drug interaction

  2000cited by this paper
• The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin.

  1999cited by this paper
• Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole

  1998cited by this paper
• Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem

  1998cited by this paper
• The area under the plasma concentration–time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin

  1998cited by this paper
• Active Secretion of Drugs from the Small Intestinal Epithelium in Rats by P‐Glycoprotein Functioning as an Absorption Barrier

  1996cited by this paper
• Reversal of daunorubicin resistance in P388/ADR cells by itraconazole.

  1991influential reference
• Efficacy and safety of oral nadolol for exercise-induced ventricular arrhythmias.

  1987cited by this paper
• Metoprolol: A Review of its Pharmacological Properties and Therapeutic Efficacy in Hypertension and Angina Pectoris

  1977cited by this paper

• Pediatric off-label use and nonadherence management for nadolol: A mechanistic PBPK model Incorporating Ontogeny Scaling from Interracial Adults to Children.

  2025cites this paper
• Dietary influences on the pharmacokinetics of antihypertensive drugs: a review of food-drug interactions

  2025cites this paper
• Pharmacokinetic Interactions of Fruit Juices with Antihypertensive Drugs in Humans: A Systematic Review and Meta-analyses.

  2025cites this paper
• Limited Sampling Strategy for Predicting the Area under Plasma Concentration–Time Curve of Nadolol in Healthy Subjects

  2024influential citation
• A Comprehensive Physiologically Based Pharmacokinetic Model of Nadolol in Adults with Renal Disease and Pediatrics with Supraventricular Tachycardia

  2024influential citation
• A HPLC-MS/MS method for the determination of Nadolol in rat plasma: Development, validation, and application to pharmacokinetic study

  2023cites this paper
• A narrative review on clinical trials showing contraindicated drugs with grapefruit juice

  2023cites this paper
• Application of a gut-liver-on-a-chip device and mechanistic modelling to the quantitative in vitro pharmacokinetic study of mycophenolate mofetil.

  2022cites this paper
• Food effects on gastrointestinal physiology and drug absorption.

  2022cites this paper
• Holothuria Leucospilota polysaccharides alleviate hyperlipidemia via alteration of lipid metabolism and inflammation-related gene expression.

  2022cites this paper
• Clinical pharmacokinetics of nadolol: A systematic review

  2022cites this paper
• Drug Interactions Affecting Antiarrhythmic Drug Use

  2022cites this paper
• Phytomedicines: Synergistic and antagonistic phytometabolites-drug interactions

  2021cites this paper
• Urinary Excretion of Nadolol as a Possible In Vivo Probe for Drug Interactions Involving P‐Glycoprotein

  2021cites this paper
• Predicting Interactions between Rifampin and Antihypertensive Drugs Using the Biopharmaceutics Drug Disposition Classification System

  2020cites this paper
• Evaluation of the Role of P-glycoprotein (P-gp)-Mediated Efflux in the Intestinal Absorption of Common Substrates with Elacridar, a P-gp Inhibitor, in Rats

  2020cites this paper
• Effects of single green tea ingestion on pharmacokinetics of nadolol in healthy volunteers

  2020cites this paper
• Organic Anion Transporting Polypeptide (OATP) transporter expression, localization and function in the human intestine.

  2019cites this paper
• Demonstrating suitability of the Caco‐2 cell model for BCS‐based biowaiver according to the recent FDA and ICH harmonised guidelines

  2019cites this paper
• [Pharmacokinetic risk factors of beta-blockers overdose in the elderly: Case report and pharmacology approach].

  2018cites this paper
• Elucidation of Substrate Binding Interactions for Human Organic Cation Transporters 1 (SLC22A1) and 2 (SLC22A2) Using In Silico Homology Modeling in Conjunction with In Vitro Site-Directed Mutagenesis and Kinetic Analysis

  2018cites this paper
• A Generic Model for Quantitative Prediction of Interactions Mediated by Efflux Transporters and Cytochromes: Application to P-Glycoprotein and Cytochrome 3A4

  2018cites this paper
• Organic solute carrier 22 (SLC22) family: Potential for interactions with food, herbal/dietary supplements, endogenous compounds, and drugs

  2018cites this paper
• Intestinal Drug Interactions Mediated by OATPs: A Systematic Review of Preclinical and Clinical Findings.

  2017cites this paper
• The Nonmetabolized β-Blocker Nadolol Is a Substrate of OCT1, OCT2, MATE1, MATE2-K, and P-Glycoprotein, but Not of OATP1B1 and OATP1B3.

  2016cites this paper
• Antibiotics and Drugs: Drug–Nutrient Interactions

  2016cites this paper
• Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies.

  2015cites this paper
• Effect of the potent CYP2D6 inhibitor sarpogrelate on the pharmacokinetics and pharmacodynamics of metoprolol in healthy male Korean volunteers

  2015cites this paper
• Effects of b-Blockers and Tricyclic Antidepressants on the Activity of Human Organic Anion Transporting Polypeptide 1 A 2 ( OATP 1 A 2 ) s

  2015cites this paper
• Effects of β-Blockers and Tricyclic Antidepressants on the Activity of Human Organic Anion Transporting Polypeptide 1A2 (OATP1A2)

  2015cites this paper
• Enhanced Boosting of Oral Absorption of Lopinavir Through Electrospray Coencapsulation with Ritonavir.

  2015cites this paper
• Clarification of P-glycoprotein inhibition-related drug–drug interaction risks based on a literature search of the clinical information

  2014influential citation
• Effects of β -blockers and tricyclic antidepressants on the activity of human organic anion transporting polypeptide 1A2 (OATP1A2)

  2014cites this paper
• Green Tea Ingestion Greatly Reduces Plasma Concentrations of Nadolol in Healthy Subjects

  2014cites this paper
• Effects of β -blockers and tricyclic antidepressants on the activity of human organic anion transporting polypeptide 1A2 (OATP1A2)

  2014cites this paper
• Effects of itraconazole, dexamethasone and naringin on the pharmacokinetics of nadolol in rats.

  2013cites this paper